The EU Commission monitors whether patent settlements concluded between pharmaceutical companies infringe EU antitrust rules

On 12 January 2010, the European Commission sent an information request to a number of pharmaceutical companies, seeking copies of their patent settlement agreements, to check their compliance with EU antitrust rules (Official Press Release IP/10/12), as a follow up to its pharmaceutical sector inquiry (Case COMP/39.514) [1]. The Commission is in particular looking at patent settlements where an originator company pays off a generic competitor in return for delayed market entry of a generic drug (so-called “reverse payments patent settlements”). This suggests that the Commission may be initiating a program to periodically monitor settlement agreements and could launch infringement proceedings against settlements it finds anticompetitive. In making this request, the Commission may have

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Frances M. Murphy, Francesco Liberatore, The EU Commission monitors whether patent settlements concluded between pharmaceutical companies infringe EU antitrust rules, 12 janvier 2010, e-Competitions January 2010, Art. N° 33751

Visites 2152

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues